@pauledward
Excellent points.
Licensing deals are the top priority, at the right price.
However, the time, effort and money would appear to be of the Austrian researchers. Patrys may have solely provided the IP rights to work with SM6, and a sample for comparative analysis.
That SM6 was chosen as the focus of this breakthrough, is evidence of Patrys's global standing.
Their network is now displayed to be stronger than previously known, with institutions encompassing Amgen/Onyx/MM/Swan/Germany/Austria/Sydney/Melbourne/etc.
The announcement of achieving gylcoprotein/binding similarity AS WELL AS rapid low cost production of IgM was an exceptional achievement. IgM is a highly complex protein, this success will have attracted interest throughout the pharma world. Amgen will now be looking over their shoulder, licensing deals have just increased in value.
@pauledwardExcellent points. Licensing deals are the top...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $14.40M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.7¢ | $43.28K | 6.183M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 237374 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1732079 | 8 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| PAB (ASX) Chart |